Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients by Franken, L.G.W. (Linda) et al.
THERAPEUTICS
Population pharmacodynamic modelling of
midazolam induced sedation in terminally ill
adult patients
Correspondence Linda G. Franken, Department of Hospital Pharmacy, Erasmus Medical Centre, Wytemaweg 80 NA-206, 3015 CN
Rotterdam, The Netherlands. Tel.: +31 1 0703 3202; Fax: +31 1 0703 2400; E-mail: l.franken@ersmusmc.nl
Received 12 April 2017; Revised 11 September 2017; Accepted 13 September 2017
Linda G. Franken1 , Brenda C. M. de Winter1, Anniek D. Masman2,3, Monique van Dijk3, Frans P. M. Baar2,
Dick Tibboel3, Birgit C. P. Koch1, Teun van Gelder1 and Ron A. A. Mathot4
1Department of Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, The Netherlands, 2Palliative Care Centre, Laurens Cadenza, Rotterdam, The
Netherlands, 3Intensive Care, Department of Paediatric Surgery, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands, and 4Hospital
Pharmacy – Clinical Pharmacology, Academic Medical Centre, Amsterdam, The Netherlands
Keywords NONMEM, palliative care, pharmacodynamics, sedation
AIMS
Midazolam is the drug of choice for palliative sedation and is titrated to achieve the desired level of sedation. A previous
pharmacokinetic (PK) study showed that variability between patients could be partly explained by renal function and
inﬂammatory status. The goal of this study was to combine this PK information with pharmacodynamic (PD) data, to evaluate the
variability in response to midazolam and to ﬁnd clinically relevant covariates that may predict PD response.
METHOD
A population PD analysis using nonlinear mixed effect models was performed with data from 43 terminally ill patients. PK
proﬁles were predicted by a previously described PK model and depth of sedation was measured using the Ramsay sedation
score. Patient and disease characteristics were evaluated as possible covariates. The ﬁnal model was evaluated using a visual
predictive check.
RESULTS
The effect of midazolam on the sedation level was best described by a differential odds model including a baseline probability,
Emax model and interindividual variability on the overall effect. The EC50 value was 68.7 μg l–1 for a Ramsay score of 3–5 and
117.1 μg l–1 for a Ramsay score of 6. Comedication with haloperidol was the only signiﬁcant covariate. The visual predictive check
of the ﬁnal model showed good model predictability.
CONCLUSION
We were able to describe the clinical response to midazolam accurately. As expected, there was large variability in response
to midazolam. The use of haloperidol was associated with a lower probability of sedation. This may be a result of
confounding by indication, as haloperidol was used to treat delirium, and deliria has been linked to a more difﬁcult sedation
procedure.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• In terminally ill patients, pharmacokinetic variability can be reduced by taking in to account a patients’ albumin levels
and estimated glomerular ﬁltration rate.
• There is large interindividual variability in clinical response to midazolam.
• Delirious patients are regarded as more difﬁcult to sedate in general, as well as in the case of palliative sedation.
WHAT THIS STUDY ADDS
• Using a population approach with categorical sedation scores, we were able to describe the pharmacodynamics of
midazolam accurately in terminally ill patients.
• Haloperidol as comedication was associated with lower Ramsay scores, and therefore a less sedative state.
• With this population pharmacodynamic model target levels of midazolam can be attained that can be used in the devel-
opment of an individualized dosing algorithm.
Table of Links
LIGANDS
Midazolam
This Table lists key ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for
data from the IUPHAR/BPS Guide to PHARMACOLOGY [1].
Introduction
In terminally ill end-of-life patients, the most important goal
is to provide adequate symptom relief [2–4].When symptoms
are so severe that none of the conventional modes of treat-
ment are effective within a reasonable time frame and/or
these treatments are accompanied by unacceptable side ef-
fects, i.e. in case of refractory symptoms, palliative sedation
may be initiated. In a hospice setting palliative sedation is
commonly used. Several studies looked at how often pallia-
tive sedation was initiated and showed that on average 46%
(range 22–67%) of the terminally ill patients in a hospice
were being sedated for refractory symptoms at the end of life
[5–9]. The drug of choice to achieve palliative sedation is mid-
azolam [5, 10]. Althoughmidazolam has been shown to be ef-
fective in achieving adequate sedation, the response between
patients varies widely. In clinical practice, the midazolam
dose is titrated according to clinical response which results
in a wide range of both effective dose and time to adequate se-
dation [11, 12]. Furthermore, the study by Morita et al.
showed that almost half of the patients awoke at least once
from the sedated state [12].
A more individualized dose could therefore potentially
lead to more adequate sedation in these patients. To investi-
gate this, a population pharmacokinetic (PK) model was de-
veloped which demonstrated large interindividual
variability (IIV) on clearance of both midazolam and its me-
tabolites with values ranging from 49 to 61% [13]. It also
showed that IIV could be signiﬁcantly reduced if patients’ se-
rum albumin levels and estimated glomerular ﬁltration rate
(eGFR) were to be taken into account. This suggests that a
dosing regimen based on albumin levels and eGFR may result
in better clinical outcome. However, such a PK model only
predicts midazolam concentrations and does not include
the pharmacodynamic (PD) variability, which is likely to be
considerable and may vary with age, sex or disease severity
[14–16]. This information is crucial when generating an indi-
vidualized dosing advice.
To investigate the clinical response to midazolam plasma
concentration on sedation level, to assess the amount of var-
iability and to ﬁnd clinically signiﬁcant covariates, we per-
formed a population PD study in terminally ill adult
patients using the Ramsay sedation score.
Methods
Study design
The study (NL32520.078.10) was approved by the Medical
Ethics Committee of the Erasmus University Medical
Centre Rotterdam and was performed in accordance with
the principles of the Declaration of Helsinki and its later
amendments. The design of the study and study popula-
tion are presented in detail in the article of Franken et al.
in which the population PK model of midazolam is
described [13]. Parts of the methods are brieﬂy mentioned
in this article when relevant. The study design with sparse
regimen of random PK and PD sampling is shown in
Figure 1.
Data collection
Demographic characteristics (age, sex, ethnicity, primary di-
agnosis and time of death) were extracted from the electronic
medical records. Midazolam administration times were re-
corded in the patient record as well as any concomitant med-
ication. Sparse blood samples were collected at random time
points during both the preterminal and terminal stage of
the disease. Using these samples, midazolam and its two
major metabolites, 1-hydroxymidazolam (1-OH-M) and
1-hydroxymidazolam glucuronide (1-OH-MG) were
PD of midazolam induced sedation in terminally ill
Br J Clin Pharmacol (2018) 84 320–330 321
determined by an liquid chromatography–tandemmass spec-
trometry method described before [13]. Blood samples for
clinical chemistry were taken at the same time and serum
levels of albumin, creatinine, urea, bilirubin, γ-glutamyl
transpeptidase, alkaline phosphatase, alanine transaminase,
aspartate transaminase and C-reactive protein were deter-
mined. Sedation was assessed using the Ramsay sedation
score and was typically scored at the start of the midazolam
treatment with consecutive assessments at 2-h intervals
[17]. This scale consists of six sedation levels: 1, patient is
anxious and agitated or restless; 2, patient is cooperative, ori-
entated and tranquil; 3, patient is drowsy or asleep and re-
sponds to commands only; 4, patient is asleep and has a
brisk response to a light glabellar tap or loud auditory stimu-
lus; 5, patient is asleep and has a sluggish response to a light
glabellar tap or loud auditory stimulus; 6, patient is asleep
and has no response to a glabellar tap or loud auditory stimu-
lus. The Ramsay sedation score has been used before in a pal-
liative care setting and enables doctors and nursing staff to
assess the level of sedation as self-reporting is usually not pos-
sible [18, 19]. The Ramsay score was measured by a trained
and experienced nurse, using a standard operating procedure.
PK data integration
A previously described population PK model was used to pre-
dict PK proﬁles for all individual patients [13]. Thismodel was
based on the same study population and contained data from
45 patients and 139 collected blood samples. This model was
systematically developed based on minimum objective func-
tion value (OFV), parameter precision, error estimates, shrink-
age values and visual inspection of the goodness of ﬁt plots,
bootstrapping and normalized prediction distribution errors
analyses. In summary the model was a one-compartment
model for both midazolam, 1-OH-M and 1-OH-MG and
contained two covariates albumin levels on midazolam clear-
ance and eGFR on 1-OH-MG clearance. Since all 43 patients
for whom Ramsay scores were available, were also included
in the PK dataset, the individual PK parameters together with
the midazolam doses were used as input for the sequential PD
model. From the remaining two patients, no Ramsay scores
were available and they were excluded from the PD model.
Population PD method
A population PD analysis using nonlinear mixed effect
models was performed with NONMEM® 7.2, in combination
with Pirana (version 2.9.2) for the model building process
and R (version 3.3.0) and PsN (version 4.6.0) to generate diag-
nostic plots.
Population PD model development
Both a proportional oddsmodel and a differential oddsmodel
were tested for the possibilities of observing a certain Ramsay
sedation score. These methods have been described before by
Kjellsson et al. and the difference between these models was
tested by dichotomising the data and performing logistic re-
gression [20]. In short, these methods estimate the logit and
corresponding probability of the Ramsay score being equal
or greater than a particular value. At any given concentration,
there is a ﬁnite probability of having a Ramsay score of 1, 2, 3,
4, 5 and 6 with the sum of these probabilities being 1. The
probability (P) of a particular sedation score (n) follows from
calculating the difference of two consecutive scores, as is
shown in equation (1).
P Ramsay ¼ nð Þ ¼ P Ramsay ≥ nð Þ  P Ramsay ≥ nþ 1ð Þ (1)
To describe the clinical response tomidazolam concentra-
tions on the probability of a certain Ramsay score linear
models, log linear models, Emax models and a sigmoidal
Emaxmodels were tested both direct and indirect [21]. Model
evaluation was based on objective function value (OFV), pa-
rameter precision, shrinkage values and visual predictive
Figure 1
Regimen of pharmacokinetic and pharmacodynamic sampling. (A) The inclusion criteria for this study were terminal illness, a survival prognosis of
more than 2 days and less than 3 months, administration of midazolam. (B) The current Dutch guidelines states that midazolam can be admin-
istered either as subcutaneous bolus injection (with a starting dose of 10mg followed 5mg every 2 h if necessary) or as a continuous subcutaneous
infusion (with a starting dose of 1,5–2.5 mg h–1 and the possibility to up the dose if sedation was insufﬁcient with 50% every 4 h in combination
with a 5-mg bolus injection). (C) In general, the Ramsay score was obtained at the start of the midazolam treatment with consecutive assessments
at 2-h intervals
L. G. Franken et al.
322 Br J Clin Pharmacol (2018) 84 320–330
checks (VPC). Pharmacodynamic parameter estimates were
obtained using the Laplacian estimationmethod. To evaluate
the effect of the midazolam metabolites, 1-hydroxy midazo-
lam (1-OH-M) and 1-hydroxy midazolamglucuronide
(1-OH-MG) an additive interaction model (equation (2)) was
used with equal maximal effect (Emax) for midazolam and
the metabolite of interest. In this equation, EC50,1 EC50,2 rep-
resent the half maximal effective concentrations of midazo-
lam and the metabolite respectively and C1 and C2
represent the concentrations of midazolam and the particular
metabolite.
Effect ¼ Emax1;2
C1
EC50;1
þ C2EC50;2
 
1þ C1EC50;1 þ
C2
EC50;2
  (2)
Covariate model development
Patient characteristics (age and sex), disease characteristics
[albumin levels, C-reactive protein levels, eGFR and time to
death (TTD)], all concomitant medication with sedatory ef-
fects and the time of day were evaluated as possible covariates
in the PD model. Signiﬁcance of a covariate was evaluated
using a forward inclusion, backward elimination method
with P-values of 0.05 and 0.001 respectively. Continuous co-
variates were incorporated using equation (3) and categorical
covariates using equation (4). All concomitant medication,
with the exception of morphine, was tested as a categorical
covariate with the value being 1 if the patients used that type
of comedication on the day of the Ramsay observations.
Morphine concentrations as well as the concentrations of
the morphine metabolites, morphine-3-glucuronide and
morphine-6-glucuronide were tested as a continuous
covariate. This was possible since the patients in this study
were also included in a population PK study on morphine
and its metabolites [22]. This PK model was used
to predict the morphine, morphine-3-glucuronide and
morphine-6-glucuronide concentrations at the time of the
Ramsay observation.
Covariate effect ¼ 1 covi
covm
 θcov
(3)
Covariate effect ¼ 1 θcov covi (4)
with covi being the individual covariate value, covm repre-
sents the median covariate value and θcov the covariate coef-
ﬁcient. In the equation for categorical covariates covi is either
1 or 0. The covariate effect that was obtained with this equa-
tion was added to the sum of the logits. Because of the trans-
formation used, a negative covariate coefﬁcient described a
positive correlation and vice versa. The difference in time be-
tween the observation and the recorded time of death was
tested as a covariate using equation (3) as well as using a ﬁrst
order equation. In this second equation (equation (5)) one
theta represents the maximum effect (θΔ) and a second theta
the rate (θrate) at which the change takes place.
Covariate effect ¼ θΔ exp θrateTTDð Þ (5)
Model evaluation
The intermediate and ﬁnal models were evaluated using the
objective function value, parameter precision and shrinkage
values. As the PD model predicts probabilities rather than ac-
tual sedation scores, residual errors could not be calculated
and the standard observed vs. predicted plots could not be
generated. We therefore used visual predictive checks to visu-
ally evaluate the goodness of ﬁt.
Results
A total of 941 Ramsay sedation scores from 43 patients were
available, with a median of 14 (interquartile range 7–30) ob-
servations per patient. The number of observations for the
Ramsay categories of 1–6 were 68 (7.2%), 161 (17.1%), 31
(3.3%), 30 (3.2%), 146 (15.5%) and 505 (53.7%), respectively.
Since there were very few data in categories 3 and 4, these
were taken together with category 5. This decision was made
as, for clinical outcome, a score of 3 or more will be sufﬁcient
in most cases. For a complete overview of the patient charac-
teristics see Table 1.
Structural model
Sedation in the terminally ill patients, using the Ramsay seda-
tion scores, was best described by a differential odds model in-
cluding a baseline probability, midazolam effect and IIV. The
effect of midazolam on the sedation was best described by a
direct Emax response model. IIV was tested on baseline,
EC50 and overall effect, where the latter gave the best results.
Incorporating more than one IIV in the model resulted in
large eigenvalues, indicating over-parameterisation. This re-
sulted in the structural model as shown by equation (6). In
this model, n represents a particular Ramsay score. Per Ram-
say score there are different baseline values and EC50 values,
but the Emax is the same for all scores.
logit Ramsay³n
  ¼ Basen þ Emax Basen
CP
CP þ EC50n þ IIV
P Ramsay³n
  ¼ elogit=2þ elogit
(6)
Implementing the concentrations of the metabolites 1-
OH-M and 1-OH-MG did not improve the model. The ﬁnal
structural model resulted in baseline probabilities of 0.23,
0.49, 0.16 and 0.13 for Ramsay scores of 1, 2, 3–5 and 6 re-
spectively and the following EC50 values 30.1, 62.8 and
111.6 μg l–1 for Ramsay scores of 2, 3–5 and 6. In the structural
model the value for IIV on overall effect was 0.81 on the logit
scale. Calculating the probability from that it means that 1SD
is equal to a probability of 69% (equation (6)).
Covariate analysis
The forward inclusion step of the covariate analysis resulted
in three signiﬁcant (P< 0.05) covariates. These were age, time
of day (night-time vs. daytime) and concomitant use of halo-
peridol. After the backward elimination step only
comedication with haloperidol remained signiﬁcant
(P < 0.001). The coefﬁcient for this effect was 1.76. Due to
the transformation used (equation (4)) patients whowere also
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treated with haloperidol had a lower probability for the seda-
tion scores 2 or higher compared to patients without haloper-
idol coadministration. The coefﬁcients, decrease in OFV and
effect on IIV in the univariate analysis of all three covariates
are shown in Table 2. The ﬁnalmodel including the use of hal-
operidol as a covariate resulted in baseline probabilities of
0.18, 0.48, 0.18 and 0.15 for Ramsay scores 1, 2 3–5 and 6 in
patients without haloperidol use and baseline probabilities
of 0.33, 0.57, 0.06 and 0.04 for Ramsay scores 1, 2 3–5 and 6
in patients with concomitant use of haloperidol (Figure 2).
The EC50 values of the ﬁnal model were the following for all
patients with and without haloperidol: 39.5, 68.7 and 117.1
μg l–1 for Ramsay scores of 2, 3–5 and 6. Figure 3 shows the
probabilities of the different Ramsay scores as a function of
the midazolam concentration. From the upper two graphs it
can be seen that, without the use of haloperidol (Figure 3A),
the probability of a Ramsay score of 3 or more is 80% at amid-
azolam concentration of about 50 μg l–1, whereas with the
concomitant use of haloperidol this concentration is around
80 μg l–1. From the bottom left graphs it is clear that at a con-
centration of 30 μg l–1 (and no haloperidol comedication) the
probabilities for a Ramsay score of 2, 3–5 and 6 are almost
equal. To also show the effect of the high IIV in themodel sim-
ulations were performed. Figure 4 shows the probabilities of a
Ramsay score of 3 or more and the probability of a Ramsay
score of 6 with their corresponding 95% conﬁdence intervals.
As mentioned before, these conﬁdence intervals are large and
as a result, the conﬁdence intervals of both scores overlap.
Model evaluation
Of the initial bootstrap of 500 runs, just over 70% resulted in
a successful covariance step and were used to calculate the 95
conﬁdence intervals. The median values and 95% conﬁdence
intervals of the bootstrap are shown in Table 3. The VPC of
the ﬁnal model showed good model predictability with the
observations (line) laying within 95% conﬁdence interval of
the model predictions (shaded area) for most of the Ramsay
scores (Figure 5). In the VPC plot it can, however, also be seen
that at midazolam concentrations of around 150–350 μg l–1,
Ramsay scores of 3–5 are somewhat over predicted while
Ramsay scores of 6 are somewhat under predicted.
Discussion
To our knowledge this is the ﬁrst study to describe the clinical
response to midazolam in terminally ill patients with a popu-
lation PDmodel. Our study population consisted primarily of
patients with cancer, admitted to a hospice, for terminal care
in the last phase of life. Others have done PD studies with
midazolam in populations of critically ill patients admitted
to intensive care units [23, 24]. For the lower Ramsay scores,
the EC50 values found in our study are in accordance with
the results of Somma et al. who studied the effect of midazo-
lam in patients after heart surgery [23]. However, the EC50
value for the highest Ramsay score in our study was less than
half of that found in the study of Somma et al. (118 vs.
352 μg l–1). A possible explanation for this difference may be
the different study populations. In our terminally ill patients,
high doses of morphine were used, whichmay have increased
the sedative effect of midazolam. However as both other stud-
ies also had opiates as comedication a more likely explana-
tion may lay the advanced illness itself. As a consequence of
their advanced illness, terminally ill patients may be unable
to respond thereby causing the overall Ramsay scores to be
higher. Furthermore, environmental factors may play a role.
A hospice setting offers more tranquillity than a hospital’s in-
tensive care unit (with more medical equipment and noises),
as described in the study of Somma et al. [23]. A more stressful
situation is also one of the arguments Swart and colleagues
Table 1
Patient characteristics of terminally ill patients receiving midazolam
Characteristics n = 43
Age, years (median, range) 71 (43–93)
Male, n (%) 22 (51.2)
Female, n (%) 21 (48.8)
Ethnic origin, n (%)
Caucasian 39 (90.7)
Afro-Caribbean 3 (7.0)
Unknown 1 (2.3)
Primary diagnosis, n (%)
Neoplasm 42 (97.7)
Disease of the respiratory system 1 (2.3)
Daily dose midazolam, mg day–1 (range) 2.5–180
Blood chemistry, serum levels at admission (median, range)
Albumin, g l–1 24 (13–38)
eGFRa, ml min–1 1.73 m–2 69.4 (6–328)
C-reactive protein, U l–1 128 (1–625)
Comedication usedb
Other benzodiazepinesc, n (%) 8 (18.6)
Haloperidol, n (%) 18 (41.9)
Levomepromazine, n (%) 2 (4.7)
Dexamethasone n (%) 13 (30.2)
Anti-epileptic drugsd, n (%) 3 (7.0)
Anti-depressant drugse, n (%) 2 (4.7)
Morphine, μg l–1 (median, range) 41.9 (0–609.2)
M3G, μg l–1 (median, range) 825.9 (0–5433.5)
M6G, μg l–1 (median, range) 119.9 (0–826.5)
Blood samples collected, n (median, range) 2 (1–10)
eGFR, estimated glomerular ﬁltration rate; M3G, morphine-3-
glucuronide; M6G, morphine-6-glucuronide
acalculated using the abbreviated MDRD equation;
bduring the same day when Ramsay observations were collected;
cBenzodiazepines used included lorazepam, oxazepam and
temazepam;
dAntiepileptic drugs used included levetiracetam and pregabaline;
eAntidepressant drugs included only amitriptyline
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[25] used to explain why their study in IC patients found even
higher EC50 values than Somma et al. [23].
In contrast to the two previously mentioned studies, we
did not only investigate the response to midazolam but also
analysed its two major metabolites 1-OH-M and 1-OH-MG.
Interestingly neither of these metabolites showed an additive
effect, while it is known from the literature that 1-OH-M is
about 80% as effective as midazolam and 1-OH-MG has a po-
tency of about 10% [25, 26]. The lack of an additive effect can
be explained by the fact that 1-OH-M is a formation rate lim-
ited metabolite, and therefore closely follows the midazolam
concentrations. As a result, it is impossible to separate the ef-
fect of these two substances. 1-OH-MG, by contrast, is elimi-
nation rate limited and it has been shown before that this
metabolite can accumulate in patients with renal failure,
causing prolonged sedation [27]. We did not see an effect of
the 1-OH-MG concentrations or renal function on sedation
in our study. The lack of an effect may be because the treat-
ment period is relatively short (palliative sedation is usually
given for around 48 h) and the dose low, compared to an
ICU setting where the starting dose may be 10 times higher
[28]. As result, the treatment period may have been too short
for any signiﬁcant accumulation to occur. Furthermore, in
palliative sedation, midazolam is not discontinued, therefore
high 1-OH-MG concentrations never occurred in the absence
of midazolam concentrations and as the sedation scale has an
upper limit an additive effect of 1-OH-MG may not be seen.
Furthermore, renal function did not seem to be that severely
affected in the population, with only 6% of the patients hav-
ing an eGFR <30 ml min–1, although it should be noted that
estimating GFR in this population is difﬁcult due to the possi-
ble low lean body weight and muscle atrophy.
The only covariate that showed a signiﬁcant effect was the
concomitant use of haloperidol. Patients who also used halo-
peridol had a higher probability of lower Ramsay scores,
meaning that they were less likely to be sedated. A possible
explanation is that this effect is a result of confounding by in-
dication, as patients receive haloperidol to treat agitation or
delirium, and deliria has been mentioned to be a risk factor
for a difﬁcult sedation process [29, 30]. The IIV did not de-
crease when haloperidol use was incorporated as a covariate.
This can be caused by the fact that the use of haloperidol
could change within an individual patient over time, and it
is therefore not a reﬂection of the IIV but rather a result of
interoccasion variability. Two other covariates – age and time
of day – showed a signiﬁcant effect in the forward inclusion
that did not hold up or stay after the backward elimination.
Age was positively correlated with sedation, meaning that el-
derly patients were more likely to be deeply sedated com-
pared to younger patients. These data are in accordance
with a study by Sun et al., who showed sedation scores after
midazolam treatment differed signiﬁcantly with age [16].
However, as the age range of patients in this study is not that
large, our patient numbers may have been too small to show a
signiﬁcant effect of age in the backward elimination step.
Time of day was also not signiﬁcant in the backward elimina-
tion step. This may be because its inﬂuence was tested using a
fairly basic dichotomous equation, with night-time vs. day-
time. A previous study by Peeters and colleagues used a more
elaborate sinus equation to describe the circadian rhythm
[31]. As our study had more sparsely collected data, this was
not feasible in our model. No correlation was found between
the sedation level and the time to death, or albumin levels, al-
though we would have expected that if a patient is closer to
the time of death (for which low albumin levels are also a
marker), they would be more deeply sedated. Incorporating
TTD and albumin as a covariate did show a trend (ΔOFV
3.27 for TTD and 3.32 for albumin). However, this did not
meet the criteria of statistical signiﬁcance. To further investi-
gate this more continuous measurements of level of sedation
may be helpful as the dying phase is a gradual process.
Table 2
Covariate effects in univariate analysis compared to the structural model
Covariatea Parameter valueb ΔOFVc ΔIIVd Included after backward elimination
Age 1.67 5.776 - 8.0% No
Use of haloperidol 1.76 11.975 + 6.3% Yes
Day vs. night-timee 0.675 4.919 + 4.1% No
aCovariates included in the full model after forward inclusion
bParameter value, note that due to the transformation used, positive values are negative correlations and vice versa
cDecrease in objective function value (OFV) after the univariate analysis
dDecrease in interindividual variability (IIV) after the univariate analysis
ewith daytime being the reference value
Figure 2
Baseline probabilities for Ramsay scores of 1, 2, 3–5 and 6 without
the use haloperidol (black bars) and with concomitant haloperidol
use (grey bars)
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Furthermore, we initially would have expected an effect of
morphine (and possibly its metabolites) on sedation levels;
however, this was not the case [32]. This could have been
caused by the fact that in 88% of the Ramsay observations
the patient also used morphine making the group of data
without morphine too small for an adequate comparison. In
addition, it is also possible that the sedative effect of mor-
phine may be less prominent in patients who have used it
for a prolonged period.
This study also a few limitations, ﬁrstly the Ramsay se-
dation score is not validated for terminally ill patients. In
addition, the scores are measured only at certain time
points, thereby making it difﬁcult to evaluate a possible de-
lay in response onset. Due to the limited number of
observations shortly after a midazolam dose, we were un-
able to include an effect compartment and to estimate a
ﬁrst-order effect compartment rate constant (Ke0). Although
midazolam has a rapid onset and we therefore would not
expect a great variability in this Ke0 value, it would be in-
teresting to see if there is any variability on Ke0 as this
would impact the onset of sedation and is therefore of con-
siderable clinical interest. To evaluate this, a more continu-
ous PD observation method such as EEG measurements
would be needed.
Another limitation in our model is that the Ramsay scores
of 3, 4 and 5 were taken together as one category due to the
limited data in the 3 and 4 categories. This is most likely also
to be a consequence of the lack of observations shortly after a
Figure 4
Simulations of the average probabilities and corresponding 95% conﬁdence intervals (dashed lines) of Ramsay score 3 or more (black) and Ramsay
score 6 (grey) without the use of haloperidol on the left (A) and with concomitant haloperidol use on the right (B)
Figure 3
(A) Probabilities of a Ramsay score ≥2 (blue) ≥3 (green) and ≥6 (purple) without the use of haloperidol. (B) Probabilities of a Ramsay score ≥2 (blue)
≥3 (green) and ≥6 (purple) with concomitant haloperidol use. (C) Probabilities of a Ramsay score of 1 (red), 2 (blue), 3–5 (green) and 6 (purple)
without the use of haloperidol. (D) Probabilities of a Ramsay score of 1 (red), 2 (blue), 3–5 (green) and 6 (purple) with concomitant haloperidol use
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midazolam dose. We also tested a model with all categories
separately, which resulted in similar parameter estimates
and almost equal EC50 values and baseline probabilities for
the scores 3, 4 and 5, as expected due to the low number of
observations. This will not affect our results and conclusions.
The main goal of palliative sedation is to make sure the pa-
tient is comfortable and although this is not exactly reﬂected
by the Ramsay score, a score of 2 or 3 or more will be
Table 3
Population pharmacodynamic parameter estimates of the structural and ﬁnal models
Parameter
Structural
model
Final
model
RSE
%
Shrinkage
%
Bootstrap of the ﬁnal model
Average 95% CI (lower) 95% CI (upper)
Baseline
B2 1.22 1.47 32 1.33 0.46 2.15
B3–5 0.91 0.72 19 0.81 2.53 0.98
B6 1.93 1.76 38 1.83 4.58 0.59
Emax model
Emax 4.08 4.62 24 4.54 3.57 6.30
EC502 (μg l
–1) 30.1 39.5 69 33.4 7.1 109.3
EC503–5 (μg l
–1) 62.8 68.7 51 62.8 10.9 165.0
EC506 (μg l
–1) 111.6 117.1 50 109.4 23.6 280.0
Covariate effect
haloperidol 1.76 18 1.74 0.88 2.41
Interindividual variability
Overall effect 0.81 0.92 29 18 0.94 0.45 1.63
Bn, baseline logit for a Ramsay score of n; Emax, maximum effec; EC50n, concentration at half of the maximum effect for a Ramsay score of n
Figure 5
Visual predictive check of the ﬁnal model for Ramsay scores of 1, 2, 3–5 and 6. With the line depicting the observed probabilities and the shaded
area the 95% prediction interval of the model. Yellow lines are the concentration intervals
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sufﬁcient. The distinction between scores 3–5 and 6 may be
relevant from the point of view of the relatives and for side
effects.
A third limitation of our study is that individual PK pa-
rameters were used from a previously performed PK model-
ling study, instead of a simultaneous PK/PD analysis. This
may have led to some overestimation of the IIV in the PD
model. Finally, previously performed PD studies on midazo-
lam included a naive pooled analysis to assess the model ac-
curacy [23, 33]. We instead used a VPC for the model
evaluation, which is a newer evaluation method and has the
additional beneﬁt that it also shows the amount of variability
in the model. In conclusion, we described the response to
midazolam on sedation levels in terminally ill patients using
a population PD model with the Ramsay sedation score as
outcome variable.
Therapeutic implications
As expected, the variability in response was large. We found
that the use of haloperidol was correlated with a lower re-
sponse. This effect is best visualized by Figure 4, where the
graph in 4A shows that without haloperidol use a typical indi-
vidual (solid line) will have an 80% chance of a Ramsay score
of 3 or more at midazolam concentration of around 50 μg l–1.
The graph also shows that due to the large interindividual
variability, a concentration of around 200 μg l–1 would be
needed to assure this same chance for 95% of the population
(dashed line). The adjacent Figure 4B shows that with con-
comitant haloperidol, the midazolam concentration needed
to give a typical patient (solid line) an 80% change of a
Ramsay score of 3 or more would be around 80 μg l–1. Again,
to ensure this chance for 95% of the population a much
higher concentration would be needed (of approximately
600 μg l–1) due to the large IIV (dashed line, Fig 4). Of course,
aiming for the higher midazolam concentrations will also in-
crease the probability of Ramsay score of 6 (grey lines), which
may not always be desirable.
Combining these results with our previous knowledge of
the PK of midazolam we performed some simulation of dos-
ing regimens for patients with and without the haloperidol
as concomitant medication and different albumin levels.
The results are shown in Table 4 and it can be seen that the
loading dose depends on the use of haloperidol and the addi-
tional doses on the albumin concentrations. For instance, a
loading dose of 7.5 mg followed by 2mg every 4 h to a patient
without haloperidol use and an albumin levels of 25 g l–1 will
on average give an 85% of a Ramsay score of 3 or more (with
its 95% conﬁdence interval between 48 and 97%). This dose
is slightly lower than the current guidelines. However, aiming
for an 80% change of a Ramsay of 3 or more for 95% of the
population would result in higher doses than the current
guidelines, especially in patients with haloperidol as
comedication. These values may be used as a reference in de-
veloping an individualized dosing regimen, which may im-
prove clinical care for these terminally ill patients. However,
it should be noted that with increasing the target concentra-
tion to ensure an adequate level of sedation for a larger pro-
portion of the population, overdosing in part of the
population would occur. It may therefore be advantageous
to initially dose with the aim to achieve a 80% chance of an
adequate sedation (Ramsay ≥3) for the typical patient and to
titrate up according to the clinical response. To achieve an ad-
equate response as soon as possible, the dose could be in-
creased if adequate sedation is not yet reached at the time of
the additional dose (after 4 h). For patients without haloperi-
dol, increasing the additional dose with 50% with a bolus of
6 mg would ensure that the concentrations at which 95% of
the population will have an 80% chance of adequate sedation
will be reached within 12 h. For patients with haloperidol
use, doubling the additional dose (with a maximum increase
of 10 mg) in combination with an 8 mg bolus would ensure
these higher concentration within around 16 h. Figure 6
shows the concentrations time proﬁles and corresponding
probabilities that would be achieved with these dosing regi-
mens. However, as the IIV remains high more research re-
mains necessary to explore further the possible underlying
causes. Other interests for future study arising from our re-
sults would be a PD study with a continuous observation to
investigate variability in onset of sedation and the effect of
haloperidol on sedation. A continuous measurement using a
Bispectral Index Monitor (BIS) has been tested before in ter-
minally ill patients. However, large variability in BIS values
for patients with Ramsay scores of 6 were found [19]. Al-
though it may give insight in the onset of sedation, BIS values
may be more difﬁcult to use for clinical recommendations.
The same goes for other continuous PD measurements such
as saccadic eye movement analysis [34]. With haloperidol it
would be interesting to investigate if the correlating is due
to the effect of deliria or because of a paradoxal response on
Table 4
Simulated dosing regimens and corresponding probabilities
– haloperidol
+ haloperidol
albumin 15 g l–1 albumin 25 g l–1 albumin 15 g l–1
Dosing regimena (mg) 7.5 / 1 25 / 4 7.5 / 2 25 / 7 10 / 1.5 75 / 12 10 / 3 75 / 21
Midazolam concentration (μg l–1) 50 200 60 200 75 600 85 600
Ramsay ≥ 3 Mean (95% CI; %) 82 (42–97) 96 (80–99) 85 (48–97) 96 (80–99) 78 (36–96) 96 (81–99) 81 (41–96) 96 (81–99)
Ramsay = 6 Mean (95% CI; %) 54 (16–88) 90 (60–98) 60 (19–90) 90 (60–98) 49 (13–86) 94 (73–99) 54 (16–88) 94 (73–99)
adosing regimen in loading dose / additional doses every 4 h
CI, conﬁdence interval
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haloperidol [35, 36]. Future research is complicated due to the
complexity of the clinical setting in palliative care, such as
the process of disease, comorbidities and the lack of validated
rating scales. However, more insight is needed and more
PK/PD research is needed to improve the care of these pa-
tients. Validated PD endpoints are necessary and a focus on
relevant questions such as onset of sedation of relief of
symtoms is needed.
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